Name: 글로벌 시장 동향
SKU: PH7214
Availability: InStock

보고서 요약(국문)

개요
전 세계 모르퀴오 증후군 치료 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
모르퀴오 증후군은 소아의 뼈와 척추, 장기, 신체 능력에 영향을 미치는 드문 유전 질환입니다. 이 질환을 가진 아이들은 체내에서 자연적으로 생성되는 당 사슬을 대사하는 효소가 부족하거나 충분히 생성하지 못합니다. 이러한 당 사슬은 세포, 혈액, 힘줄, 인대에 축적되어 시간이 지남에 따라 마모와 손상을 유발합니다. 2014년 미국 식품의약국(FDA)은 모르퀴오 증후군 4기(MPS IV) 치료를 위해 재조합 인간 GALNS 효소 대체 요법(엘로술파제 알파, 또는 비미짐)을 승인했으며, 다른 모르퀴오 증후군 4기(MPS IV) 치료법은 증상 완화 및 보조 요법에 그칩니다.

모르퀴오 증후군은 소아의 뼈와 척추, 장기, 신체 능력에 영향을 미치는 드문 유전 질환입니다. 시장 동향: 성장 동인 및 제약 요인
규제 기관의 승인
기존 모르퀴오 증후군 치료제에 대한 새로운 승인과 여러 규제 기관의 지원 증가는 예측 기간 동안 세계 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2019년 6월 바이오마린 제약(BioMarin Pharmaceutical Inc.)은 모르퀴오 A 증후군으로도 알려진 4A형 점액다당증(MPS IVA) 환자 치료를 위한 비미짐(엘로술파제 알파)에 대해 중국 국가약품감독관리국(NMPA)의 승인을 받았습니다. 비미짐은 중국에서 이 질환에 대해 승인된 최초의 치료제입니다.
또한, 영국 국립보건임상연구소(NICE)는 2022년 3월, 4A형 점액다당증(MPS 4A 및 모르퀴오 A 증후군으로도 알려짐) 치료를 위해 엘로술파제 알파(비미짐, 바이오마린 제조)의 NHS(영국 국민보건서비스) 내 반복 사용을 권고하는 최종 가이드라인 초안을 발표했습니다. 또한, 연구 활동 증가, 인식 제고 및 유병률 증가는 예측 기간 동안 세계 시장 성장을 촉진할 것으로 예상됩니다.
높은 치료 비용
높은 치료 비용은 예측 기간 동안 세계 시장 성장을 저해할 것으로 예상됩니다. 예를 들어, 일부 국가에서 엘로술파제 알파의 비용은 연간 2,080,000달러에서 6,240,000달러에 이르러 일부 의료 보험 플랜에서 감당하기 어려울 수 있습니다. 또한, 치료 선택의 제한, 낮은 유병률 및 높은 신약 개발 비용 또한 예측 기간 동안 세계 시장 성장을 저해할 것으로 예상됩니다.
세분화 분석
세계 모르퀴오 증후군 치료 시장은 유형, 치료법, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
MPS IV A형이 시장을 주도할 것으로 예상
긍정적인 연구 결과 증가와 MPS IV B형보다 높은 유병률로 인해 MPS IV A형이 예측 기간 동안 세계 시장을 주도할 것으로 예상됩니다. 예를 들어, 스페인 바르셀로나 자치대학교(UAB) 연구팀은 뮤코폴리사카리도증 4형(MPS IV) 환자에게 나타나는 모든 장애 증상을 종합적으로 보여주는 최초의 쥐 모델을 개발했습니다. 이 연구팀은 단 한 번의 정맥 내 바이러스 벡터 투여만으로 쥐 모델에서 나타나는 극심한 전신 변화를 완전히 회복시키는 유전자 치료법까지 개발했습니다. 이는 이 희귀 질환을 진단받은 어린 환자들에게 조기에 투여하여 뼈 기형, 골관절염 합병증, 기타 생명을 위협하는 질환을 예방할 수 있는 가능성을 열어줍니다.
또한, 미국 희귀질환협회(NORAD)에 따르면 MPS IV 환자의 95%에서 MPS IVA가, 약 5%에서 MPS IVB가 발견됩니다.

지리적 분석
북미, 세계 시장 주도 예상
연구 활동 및 자금 지원 증가로 북미 시장이 성장하여 예측 기간 동안 세계 시장을 주도할 것으로 예상됩니다. 예를 들어, 2023년 5월, 미국 국립보건원(NIH) 산하 재단(FNIH)의 가속화된 의약품 파트너십 맞춤형 유전자 치료 컨소시엄(AMP BGTC)의 일환으로 네무어스 어린이 건강 센터(Nemours Children's Health)가 모르퀴오 A 증후군에 대한 최초의 유전자 치료 임상 시험을 수행하도록 선정되었습니다.
또한, 2023년 8월에는 모르퀴오 증후군 및 기타 7가지 초희귀 질환 환자를 대상으로 유전자 치료를 시험하는 데 필요한 9,700만 달러의 자금과 전문 지식을 제공하는 특별한 계획이 수립되어, 내년부터 이 계획이 시행될 예정입니다. 이 프로그램은 비영리 단체, 정부 기관 및 산업계가 참여하는 연합체로, 비영리 단체인 미국 국립보건원 재단이 주도합니다. 더불어, 질환에 대한 인식 증가와 유병률 상승 또한 예측 기간 동안 북미 지역 시장 성장에 기여하고 있습니다.
COVID-19 영향 분석
효소 대체 요법(ERT)은 특정 유형의 리소좀 축적 질환(LSD)에 대한 일반적인 치료법으로, 주 1회 또는 격주로 정맥 주사를 통해 투여합니다. ERT는 일부 유형의 뮤코폴리사카리도증(MPS) 환자에서 호흡기 및 심장 기능 개선, 장기 비대 완화, 관절 가동 범위 향상, 전반적인 건강 관련 삶의 질 개선에 효과적인 것으로 나타났습니다.
그러나 COVID-19 팬데믹으로 인해 정기적인 ERT 투여가 차질을 빚으면서 전 세계 시장 성장에 부정적인 영향을 미쳤습니다. 리소좀 축적 질환은 호흡기, 신장, 심장 기능과 관련되어 있어 고위험 질환으로 분류됩니다. COVID-19 팬데믹은 ERT 투여의 차질을 초래하여 전 세계 시장 성장에 상당한 영향을 미쳤습니다.

시장 세분화
치료법별
• 효소 대체 요법
o 비미짐(엘로술파제 알파)
• 보조/증상 완화 요법
o 진통제
o 건강 보조제
o 기타
• 기타
유형별
• MPS IV A형
• MPS IV B형
투여 경로별
• 주사제
• 경구제
• 기타
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 동향
• 2022년 3월, 영국 국립보건임상연구소(NICE)는 최종 권고안을 발표했습니다. 영국 국민보건서비스(NHS)에서 4A형 점액다당증(MPS 4A) 또는 모르퀴오 A 증후군 치료를 위해 바이오마린(BioMarin)에서 생산하는 비미진(Vimizin)이라는 엘로술파제 알파를 반복적으로 사용할 것을 권장하는 가이드라인 초안입니다.
• 2019년, 바이오마린 제약의 비미진(엘로술파제 알파)은 중국 국가약품감독관리국(NMPA)으로부터 4A형 점액다당증(MPS 4A) 또는 모르퀴오 A 증후군 환자 치료제로 승인을 받았습니다. 이는 중국에서 이 희귀 질환에 대한 최초의 승인된 치료제입니다.
경쟁 환경
주요 글로벌 시장 참여 기업으로는 바이오마린, JCR Pharmaceuticals Co., Ltd., 노바티스(Novartis AG), 다케다 제약(Takeda Pharmaceutical Company Limited.), 알렉시온 제약(Alexion Pharmaceuticals, Inc.), 리젠스바이오(Regenxbio Inc.), 울트라제닉스 제약(Ultragenyx Pharmaceutical Inc.), 애브비(Abbvie Inc.), 아베오나 테라퓨틱스(Abeona Therapeutics Inc.) 등이 있습니다.
보고서 구매 이유

• 유형, 치료법, 투여 경로, 유통 채널 및 지역별 글로벌 모르퀴오 증후군 치료 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 모르퀴오 증후군 치료 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 모르퀴오 증후군 치료 시장 보고서는 약 69개의 표, 67개의 그림, 192페이지 분량입니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Morquio Syndrome Therapy market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Morquio syndrome is a infrequent genetic disorder impacting a child’s bones and spine, organs, and physical capabilities. Kids with this disorder are deficient or do not produce sufficient amounts of the enzymes that metabolizes sugar chains inherently produced in the body. These chains stockpile in cells, blood, tendons, and ligaments, inducing wear and trear over time. In 2014, the FDA authorized a recombinant human GALNS enzyme replacement therapy (elosulfase alfa, or Vimizim) for the treatment of MPS IVA while other therapy of MPS IV is symptomatic and supportive.
Market Dynamics: Drivers & Restraints
Authorizations From Regulatory Bodies
The new approvals for the existing Morquio Syndrome therapy and increasing support from distinct regulatory authorities are expected to boost the global market growth during the forecast period. For instance, in June 2019, BioMarin Pharmaceutical Inc. obtained the National Medical Products Administration (NMPA) approval for its Vimizim (elosulfase alfa) in the treatment of individuals with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. Vimizim is the first treatment in China approved for this condition.
Moreover, the NICE in March 2022, issued the conclusive draft guidance suggesting elosulfase alfa (also called Vimizin and made by BioMarin) for recurring usage in the NHS for the therapy of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome). Furthermore, the increasing research activities, growing awareness and plrevalence are also expected to boost the global market growth during the forecast period.
High Therapy Cost
The high cost of the therapy is expected to hamper the global market growth during the forecast period. For instance, the cost of elosulfase alfa in few nations is in beyween $2,080,000 to $6,240,000 per year, making it problematic for some health plans to afford it. Furthermore, the low treatment choices, low prevalence and high drug development costs are also expected to hamper the global market growth during the forecast period.
Segment Analysis
The global morquio syndrome therapy market is segmented based on type, therapy, route of administration, distribution channel and region.
MPS IV Type A is Expected to Dominate Market
Owing to the increase in positive research investigation outcomes and high prevalence of MPS IV Type A than MPS IV Type B, it is estimated to dominate the global market during the forecast period. For instance, a team at the Universitat Autònoma de Barcelona (UAB), Spain, has developed the first rat model summarizing all disabling alterations encountered by individuals with Mucopolysaccharidosis type IVA, also termed Morquio A disease. The team has even created a gene therapy that fully restores the extreme whole-body alterations in the rat model after a single intravenous viral vector administration, opening the door to a prospective therapy that might be administered at young ages in patients detected with this rare disease, thereby averting bone malformations, osteoarthritic intricacies, and other life-threatening alterations.
Moreover, according to the National Organization for Rare Disorders, Inc. MPS IVA is detected in 95% of individuals impacted by MPS IV while MPS IVB is detected in around 5% of affected individuals.
Geographical Analysis
North America is Expected to Dominate the Global Market
Owing to the increase research initiatives and funding are expected to boost the North American market, dominating the global market during the forecast period. For instance, in May 2023, as a component of the Foundation for the National Institutes of Health (FNIH) Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (AMP BGTC), Nemours Children's Health has been picked to execute a first-of-its-kind gene therapy clinical trial for Morquio A syndrome.
Again, in August 2023, a unique initiative strives to eliminate hindrance, delivering $97 million in funds and expertise to assist investigators in testing gene therapy in individuals with Morquio and seven other ultrarare diseases as soon as next year. The program, a coalition of nonprofits, government, and industry, is directed by the non-profit Foundation for the National Institutes of Health. Furthermore, the growing awareness and prevalence of the condition is also contributing to the regional market growth during the forecast period.
COVID-19 Impact Analysis
Enzyme replacement therapy (ERT) is a common treatment for certain types of lysosomal storage diseases (LSDs), which involves intravenously administering weekly or biweekly doses. ERT has been found to improve respiratory and cardiac function, alleviate organomegaly, improve range of motion, and enhance the overall health-related quality of life for some types of mucopolysaccharidoses (MPS).
However, the global market growth for scheduled ERT was negatively affected due to COVID-19 disruptions. Lysosomal storage diseases are high-risk illnesses because of their involvement with respiratory, renal, and cardiac functions. The COVID-19 pandemic has also disrupted the availability of ERT, which has had a significant impact on the global market growth.
Market Segmentation
By Therapy
• Enzyme Replacement Therapy
o Vimizim (elosulfase alfa)
• Supportive/Symptomatic Therapy
o Painkillers
o Supplements
o Others
• Others
By Type
• MPS IV Type A
• MPS IV Type B
By Route of Administration
• Injectable
• Oral
• Other
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In March 2022, the National Institute for Health and Care Excellence (NICE) issued conclusive draft guidance recommending the recurring use of elosulfase alfa, also known as Vimizin and produced by BioMarin, for the treatment of mucopolysaccharidosis type 4A (MPS 4A) or Morquio A syndrome in the NHS.
• In 2019, Vimizim (elosulfase alfa) by BioMarin Pharmaceutical Inc. has received approval from the National Medical Products Administration (NMPA) to treat patients with mucopolysaccharidosis type IVA (MPS IVA) or Morquio A syndrome. This marks the first ever approved treatment for this rare condition in China.
Competitive Landscape
The major global players in the market include BioMarin, JCR Pharmaceuticals Co., Ltd., Novartis AG, Takeda Pharmaceutical Company Limited., Alexion Pharmaceuticals, Inc., Regenxbio Inc., Ultragenyx Pharmaceutical Inc., Abbvie Inc., and Abeona Therapeutics Inc. among others.
Why Purchase the Report?
• To visualize the global morquio syndrome therapy market segmentation based on type, therapy, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of morquio syndrome therapy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global morquio syndrome therapy market report would provide approximately 69 tables, 67 figures and 192 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Therapy
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Authorizations From Regulatory Bodies
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. High Therapy Cost
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. Pipeline Analysis
5.8. Epidemiology
5.9. SWOT Analysis
5.10. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Enzyme Replacement Therapy*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Vimizim (elosulfase alfa)
7.3. Supportive/Symptomatic Therapy
7.3.1. Painkillers
7.3.2. Supplements
7.3.3. Others
7.4. Others
8. By Therapy
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
8.1.2. Market Attractiveness Index, By Therapy
8.2. MPS IV Type A*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. MPS IV Type B
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Injectable*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Oral
9.4. Other
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. BioMarin*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. JCR Pharmaceuticals Co., Ltd.
13.3. Novartis AG
13.4. Takeda Pharmaceutical Company Limited.
13.5. Alexion Pharmaceuticals, Inc., Inc.
13.6. REGENXBIO INC.
13.7. Abeona Therapeutics Inc.
13.8. AbbVie Inc.
13.9. Ultragenyx Pharmaceutical Inc.
13.10. Akero Therapeutics, Inc.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

BioMarin, 4.	Key Developments, JCR Pharmaceuticals Co., Ltd., Novartis AG, Takeda Pharmaceutical Company Limited., Alexion Pharmaceuticals, Inc., Inc., REGENXBIO INC., Abeona Therapeutics Inc., AbbVie Inc., Ultragenyx Pharmaceutical Inc., Akero Therapeutics, Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Morquio Syndrome Therapy Market Value, By Therapy, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Morquio Syndrome Therapy Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Morquio Syndrome Therapy Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Morquio Syndrome Therapy Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Morquio Syndrome Therapy Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Morquio Syndrome Therapy Market Value, By Therapy, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Morquio Syndrome Therapy Market Value, By Therapy, 2021-2030 (US$ Million)

Table 8 Global Morquio Syndrome Therapy Market Value, By Type, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Morquio Syndrome Therapy Market Value, By Type, 2021-2030 (US$ Million)

Table 10 Global Morquio Syndrome Therapy Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Morquio Syndrome Therapy Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 12 Global Morquio Syndrome Therapy Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Morquio Syndrome Therapy Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 14 Global Morquio Syndrome Therapy Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Morquio Syndrome Therapy Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Morquio Syndrome Therapy Market Value, By Therapy, 2021-2030 (US$ Million)

Table 17 North America Morquio Syndrome Therapy Market Value, By Type, 2021-2030 (US$ Million)

Table 18 North America Morquio Syndrome Therapy Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 North America Morquio Syndrome Therapy Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 North America Morquio Syndrome Therapy Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Morquio Syndrome Therapy Market Value, By Therapy, 2021-2030 (US$ Million)

Table 22 South America Morquio Syndrome Therapy Market Value, By Type, 2021-2030 (US$ Million)

Table 23 South America Morquio Syndrome Therapy Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 24 South America Morquio Syndrome Therapy Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 25 South America Morquio Syndrome Therapy Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Morquio Syndrome Therapy Market Value, By Therapy, 2021-2030 (US$ Million)

Table 27 Europe Morquio Syndrome Therapy Market Value, By Type, 2021-2030 (US$ Million)

Table 28 Europe Morquio Syndrome Therapy Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 29 Europe Morquio Syndrome Therapy Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 30 Europe Morquio Syndrome Therapy Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Morquio Syndrome Therapy Market Value, By Therapy, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Morquio Syndrome Therapy Market Value, By Type, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Morquio Syndrome Therapy Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Morquio Syndrome Therapy Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Morquio Syndrome Therapy Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Morquio Syndrome Therapy Market Value, By Therapy, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Morquio Syndrome Therapy Market Value, By Type, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Morquio Syndrome Therapy Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Morquio Syndrome Therapy Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 40 BioMarin: Overview

Table 41 BioMarin: Product Portfolio

Table 42 BioMarin: Key Developments

Table 43 JCR Pharmaceuticals Co., Ltd.: Overview

Table 44 JCR Pharmaceuticals Co., Ltd.: Product Portfolio

Table 45 JCR Pharmaceuticals Co., Ltd.: Key Developments

Table 46 Novartis AG: Overview

Table 47 Novartis AG: Product Portfolio

Table 48 Novartis AG: Key Developments

Table 49 Takeda Pharmaceutical Company Limited.: Overview

Table 50 Takeda Pharmaceutical Company Limited.: Product Portfolio

Table 51 Takeda Pharmaceutical Company Limited.: Key Developments

Table 52 Alexion Pharmaceuticals, Inc., Inc.: Overview

Table 53 Alexion Pharmaceuticals, Inc., Inc.: Product Portfolio

Table 54 Alexion Pharmaceuticals, Inc., Inc.: Key Developments

Table 55 REGENXBIO INC.: Overview

Table 56 REGENXBIO INC.: Product Portfolio

Table 57 REGENXBIO INC.: Key Developments

Table 58 Ultragenyx Pharmaceutical Inc.: Overview

Table 59 Ultragenyx Pharmaceutical Inc.: Product Portfolio

Table 60 Ultragenyx Pharmaceutical Inc.: Key Developments

Table 61 AbbVie Inc.: Overview

Table 62 AbbVie Inc.: Product Portfolio

Table 63 AbbVie Inc.: Key Developments

Table 64 Abeona Therapeutics Inc.: Overview

Table 65 Abeona Therapeutics Inc.: Product Portfolio

Table 66 Abeona Therapeutics Inc.: Key Developments

Table 67 Akero Therapeutics, Inc.: Overview

Table 68 Akero Therapeutics, Inc.: Product Portfolio

Table 69 Akero Therapeutics, Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 2 Global Morquio Syndrome Therapy Market Share, By Therapy, 2022 & 2030 (%)

Figure 3 Global Morquio Syndrome Therapy Market Share, By Type, 2022 & 2030 (%)

Figure 4 Global Morquio Syndrome Therapy Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 5 Global Morquio Syndrome Therapy Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global Morquio Syndrome Therapy Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Morquio Syndrome Therapy Market Y-o-Y Growth, By Therapy, 2022-2030 (%)

Figure 8 Enzyme Replacement Therapy Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 9 Supportive/Symptomatic Therapy Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 10 Others Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 11 Global Morquio Syndrome Therapy Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 12 MPS IV Type A Type in Global Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 13 MPS IV Type B Type in Global Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 14 Global Morquio Syndrome Therapy Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 15 Injectable Route of Administration in Global Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 16 Oral Route of Administration in Global Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 17 Other Route of Administration in Global Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 18 Global Morquio Syndrome Therapy Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 19 Hospital Pharmacies Distribution Channel in Global Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 20 Retail Pharmacies Distribution Channel in Global Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 21 Online Pharmacies Distribution Channel in Global Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 22 Others Distribution Channel in Global Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 23 Global Morquio Syndrome Therapy Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 24 North America Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 25 Asia-Pacific Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 26 Europe Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 27 South America Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 28 Middle East and Africa Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 29 North America Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 30 North America Morquio Syndrome Therapy Market Share, By Therapy, 2022 & 2030 (%)

Figure 31 North America Morquio Syndrome Therapy Market Share, By Type, 2022 & 2030 (%)

Figure 32 North America Morquio Syndrome Therapy Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 33 North America Morquio Syndrome Therapy Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 34 North America Morquio Syndrome Therapy Market Share, By Country, 2022 & 2030 (%)

Figure 35 South America Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 36 South America Morquio Syndrome Therapy Market Share, By Therapy, 2022 & 2030 (%)

Figure 37 South America Morquio Syndrome Therapy Market Share, By Type, 2022 & 2030 (%)

Figure 38 South America Morquio Syndrome Therapy Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 39 South America Morquio Syndrome Therapy Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 40 South America Morquio Syndrome Therapy Market Share, By Country, 2022 & 2030 (%)

Figure 41 Europe Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 42 Europe Morquio Syndrome Therapy Market Share, By Therapy, 2022 & 2030 (%)

Figure 43 Europe Morquio Syndrome Therapy Market Share, By Type, 2022 & 2030 (%)

Figure 44 Europe Morquio Syndrome Therapy Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 45 Europe Morquio Syndrome Therapy Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 46 Europe Morquio Syndrome Therapy Market Share, By Country, 2022 & 2030 (%)

Figure 47 Asia-Pacific Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 48 Asia-Pacific Morquio Syndrome Therapy Market Share, By Therapy, 2022 & 2030 (%)

Figure 49 Asia-Pacific Morquio Syndrome Therapy Market Share, By Type, 2022 & 2030 (%)

Figure 50 Asia-Pacific Morquio Syndrome Therapy Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 51 Asia-Pacific Morquio Syndrome Therapy Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 52 Asia-Pacific Morquio Syndrome Therapy Market Share, By Country, 2022 & 2030 (%)

Figure 53 Middle East & Africa Morquio Syndrome Therapy Market Value, 2021-2030 (US$ Million)

Figure 54 Middle East & Africa Morquio Syndrome Therapy Market Share, By Therapy, 2022 & 2030 (%)

Figure 55 Middle East & Africa Morquio Syndrome Therapy Market Share, By Type, 2022 & 2030 (%)

Figure 56 Middle East & Africa Morquio Syndrome Therapy Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 57 Middle East & Africa Morquio Syndrome Therapy Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 58 BioMarin: Financials

Figure 59 JCR Pharmaceuticals Co., Ltd.: Financials

Figure 60 Novartis AG: Financials

Figure 61 Takeda Pharmaceutical Company Limited.: Financials

Figure 62 Alexion Pharmaceuticals, Inc., Inc.: Financials

Figure 63 REGENXBIO INC.: Financials

Figure 64 Ultragenyx Pharmaceutical Inc.: Financials

Figure 65 AbbVie Inc.: Financials

Figure 66 Abeona Therapeutics Inc.: Financials

Figure 67 Akero Therapeutics, Inc.: Financials

글로벌 모르퀴오 증후군 치료 시장 – 2023-2030

Global Morquio Syndrome Therapy Market - 2023-2030